Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP -- Ignore unavailable to you. Want to Upgrade?

To: bob s who wrote (41)	11/27/1997 3:58:00 PM
From: E.J. Neitz Jr	Read Replies (1) \| Respond to of 152

Bob--Lehman Bros-indicates TRGA will announce Phase 2a trial for HP228 in post-operative pain management during 2q98. Research revenue projection for all of 97 est at 7.0 mil. Also expect chemistry deal with pharm co in 2h98. Cash seems ok at $22.5m as of 9/97--and ongoing revenue generation of about 7mil/yr. Price target $8. As for Murphy--bio certainly has not been one of his bright spots during the past year!! My personal feeling is that TRGA is caught up in the end of year rout of small biotecs. Happens every year. Good for me because I do most of my annual buys during Mid Nov-year end. If TRGA drops to $1.50 to $2/shr before year end--I will throw a party--I will be the happiest person in the world--because our buying will become very very aggressive. IMHO don't think I will be that lucky to see that price level--probably at the lows now. Best of luck.